Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Latest Information Update: 20 May 2024
At a glance
- Drugs Relugolix (Primary)
- Indications Pregnancy complications
- Focus Adverse reactions
- Sponsors Myovant Sciences; Sumitomo Pharma America
Most Recent Events
- 27 Mar 2023 Planned initiation date changed from 1 Feb 2023 to 1 Mar 2023.
- 27 Mar 2023 Status changed from not yet recruiting to recruiting.
- 24 Feb 2023 New trial record